Background: Adiponectin and resistin, as well as the novel angiogenetic factor angiogenin, may be associated with inflammation and atherosclerosis. However, the available data are limited regarding adipocytokines and angiogenesis factors long-term serum concentration changes in patients with coronary artery disease (CAD).
Aim: To evaluate the treatment strategy-dependent changes in serum concentrations of adiponectin, resistin and angiogenin in patients with stable multivessel CAD (MCAD) and their association with cardiovascular events.
Methods: The study group comprised 107 MCAD patients (80 males, mean age 63±8 years); 55 (51%) patients were treated surgically (coronary artery bypass grafting-CABG), while the other 52 (49%) were treated medically. Adiponectin, resistin and angiogenin plasma levels were measured on admission and after one-year follow-up. Major adverse cardiac events (MACE) were defined as cardiac death, non-fatal myocardial infarction, stroke or hospitalisation for angina or heart failure over the 12 month period.
Results: During one-year follow-up, nine (8%) patients died, all from cardiovascular causes, and 34 (32%) patients experienced MACE. The CABG group revealed significant decrease in angiogenin (p<0.0001) and adiponectin (p=0.03) serum levels. In the medically treated group, we noted a significant reduction in the adiponectin serum concentration (p=0.003), with no change in resistin and angiogenin serum levels.
Conclusions: In stable patients with MCAD, the choice of treatment strategy (optimal medical therapy or surgery) influences cytokines profile and modifies serum concentration of angiogenin and adiponectin during 12 months of follow-up. Assessing the dynamic concentration changes of these novel biomarkers may be useful for clinical practice.